Financial Performance - In 2025, the company achieved operating revenue of 1,676.75 million yuan, representing a year-on-year increase of 14.95% [3] - The net profit attributable to the parent company was 310.83 million yuan, up 23.48% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 305.98 million yuan, reflecting a year-on-year growth of 28.90% [3] Financial Position - As of the end of the reporting period, the company's total assets amounted to 3,646.89 million yuan, an increase of 7.33% from the beginning of the period [4] - The equity attributable to the parent company reached 3,285.55 million yuan, growing by 8.60% compared to the start of the period [4] - The net asset per share attributable to the parent company was 18.93 yuan, which is a 9.32% increase from the beginning of the period [4] Business Performance Factors - The growth in revenue for 2025 was primarily driven by the pharmaceutical and electronic materials sectors, with the pharmaceutical sector benefiting from inventory adjustments by key clients and increased sales of core products [5] - The electronic materials sector saw growth due to successful validation of semiconductor photoresist monomer materials and the introduction of certain packaging materials [5] - The company focused on enhancing operational efficiency and cost reduction, which contributed to improved profitability [5]

报告期内，显示材料板块平稳发展，2025年度收入增长主要体现在医药及电子材料板块，其中医药板块 主力产品客户调整库存策略、核心产品进一步放量，推动销售收入增长;电子材料板块随着公司半导体 光刻胶单体材料验证工作的顺利推进，并成功导入部分封装材料产品，带动了相关业务的增长。本年度 公司持续着力提升经营管理效率，深化降本增效，通过节约挖潜、精益流程进一步完善管理体系，强化 研产供销协同，降低生产成本，推动盈利能力提升。 瑞联新材(688550.SH)披露2025年度业绩快报，2025年度实现营业收入16.77亿元，同比增长14.95%;归属 于母公司所有者的净利润3.11亿元，同比增长23.48%。 ...

智通财经APP讯，瑞联新材(688550.SH)披露2025年度业绩快报，2025年度实现营业收入16.77亿元，同 比增长14.95%;归属于母公司所有者的净利润3.11亿元，同比增长23.48%。 报告期内，显示材料板块平稳发展，2025年度收入增长主要体现在医药及电子材料板块，其中医药板块 主力产品客户调整库存策略、核心产品进一步放量，推动销售收入增长;电子材料板块随着公司半导体 光刻胶单体材料验证工作的顺利推进，并成功导入部分封装材料产品，带动了相关业务的增长。本年度 公司持续着力提升经营管理效率，深化降本增效，通过节约挖潜、精益流程进一步完善管理体系，强化 研产供销协同，降低生产成本，推动盈利能力提升。 ...

Core Viewpoint - 瑞联新材 (688550.SH) reported a strong performance for the fiscal year 2025, with significant growth in both revenue and net profit, driven by advancements in its pharmaceutical and electronic materials segments [1] Financial Performance - The company achieved an operating revenue of 1.677 billion yuan, representing a year-on-year increase of 14.95% [1] - The net profit attributable to shareholders reached 311 million yuan, marking a year-on-year growth of 23.48% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 306 million yuan, reflecting a year-on-year increase of 28.90% [1] Segment Performance - The revenue growth in 2025 was primarily driven by the pharmaceutical and electronic materials segments [1] - In the pharmaceutical segment, sales revenue increased due to clients adjusting inventory strategies and a further increase in core product sales [1] - The electronic materials segment saw growth as the company successfully advanced its semiconductor photoresist monomer material validation and introduced some packaging materials products [1] Operational Efficiency - The company focused on enhancing operational management efficiency and deepening cost reduction and efficiency improvement measures [1] - Efforts included cost savings, process optimization, and strengthening the coordination of research, production, supply, and sales to lower production costs and enhance profitability [1]